Does Rallies show Form 4 insider transactions for LRMR?

Yes. Rallies tracks LRMR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LRMR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LRMR. It does not provide personalized investment advice.

LRMR (Larimar Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Larimar Therapeutics, Inc. Common Stock (LRMR) is a publicly traded Healthcare sector company. As of May 21, 2026, LRMR trades at $3.48 with a market cap of $336.58M and a P/E ratio of 0.00. LRMR moved +5.71% today. Year to date, LRMR is +5.06%; over the trailing twelve months it is +71.36%. Its 52-week range spans $1.61 to $9.50. Analyst consensus is strong buy with an average price target of $16.00. Rallies surfaces LRMR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LRMR stock inside the company?

Recent LRMR insider activity includes Flynn James E bought 1.08M, Flynn James E bought 1.08M, Flynn James E bought 831.98K, Flynn James E bought 2.00M, and Hamilton Thomas Edward bought 100.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LRMR Key Metrics

Key financial metrics for LRMR
Metric	Value
Price	$3.48
Market Cap	$336.58M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$9.50
52-Week Low	$1.61
Volume	519
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-165.67M
Gross Margin	0.00%

Recent LRMR Insider Trades

Flynn James E bought 1.08M (~$5.42M) on Feb 27, 2026.
Flynn James E bought 1.08M (~$5.42M) on Feb 27, 2026.
Flynn James E bought 831.98K (~$4.16M) on Feb 27, 2026.
Flynn James E bought 2.00M (~$10.00M) on Feb 27, 2026.
Hamilton Thomas Edward bought 100.00K (~$500.00K) on Feb 27, 2026.

Latest LRMR News

Larimar Plans June Rolling BLA Submission with $200M Cash Runway — May 14, 2026
Larimar Therapeutics Gains Breakthrough Therapy Designation and Raises $107.6M for BLA Pathway — Mar 19, 2026
Larimar Therapeutics Shares Surge 55% After FDA Grants Breakthrough Therapy Designation — Mar 6, 2026
Larimar Therapeutics price target raised to $12 after $100M offering, schedules March presentations — Mar 4, 2026
Larimar Shares Soar 66% on FDA Breakthrough Designation and Upgraded Targets — Feb 25, 2026

LRMR Analyst Consensus

5 analysts cover LRMR: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $16.00.

Common questions about LRMR

Who is trading LRMR stock inside the company?: Recent LRMR insider activity includes Flynn James E bought 1.08M, Flynn James E bought 1.08M, Flynn James E bought 831.98K, Flynn James E bought 2.00M, and Hamilton Thomas Edward bought 100.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LRMR?: Yes. Rallies tracks LRMR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LRMR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LRMR. It does not provide personalized investment advice.